Department of Endocrinology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaian, China.
Department of Neurology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaian, China.
Obes Facts. 2024;17(5):524-534. doi: 10.1159/000540701. Epub 2024 Aug 8.
Elevated levels of serum uric acid (SUA) are strongly associated with several components of the metabolic syndrome, particularly obesity. Previous studies have reported the correlation between SUA levels, xanthine oxidoreductase (XOR) activity, and the imbalanced adipokine levels that are characteristic of obesity. In this study, we explored the effect of febuxostat on circulating adipokine profiles in patients with overweight or obesity and asymptomatic hyperuricemia.
This study was a single-center, randomized, and controlled clinical trial that enrolled 130 participants with asymptomatic hyperuricemia and obesity. One hundred seventeen participants were included in the final analysis, with 60 participants in the febuxostat group and 57 in the control group. We compared the circulating adipokine levels at 3 and 6 months, including high molecular weight (HMW) adiponectin, chemerin, omentin, monocyte chemotactic protein-1, asprosin, fibroblast growth factor 21, neuregulin-4, leptin, resistin, vaspin, visfatin, adipsin, and assessed the correlation between changes in adipokine levels (Δadipokines) and changes in XOR activity (ΔXOR) after febuxostat treatment.
The results showed that an increase in HMW adiponectin and omentin levels and a decrease in chemerin and asprosin levels at 3 or 6 months compared to the control group. Additionally, a positive correlation was observed between ΔXOR activity and Δasprosin. Furthermore, after adjusting for triglyceride (ΔTG) and serum uric acid (ΔSUA) in multiple linear regression analyses, we found that ΔXOR activity was independently correlated with Δasprosin.
This study may provide important evidence that febuxostat could alleviate the imbalance in circulating adipokine levels in patients with overweight or obesity and asymptomatic hyperuricemia. Furthermore, we observed a positive correlation between changes in asprosin levels and changes in XOR activity after febuxostat treatment.
血清尿酸（SUA）水平升高与代谢综合征的多个成分密切相关，尤其是肥胖。先前的研究报告了 SUA 水平、黄嘌呤氧化还原酶（XOR）活性与肥胖特征性的不平衡脂肪因子水平之间的相关性。在这项研究中，我们探讨了非布司他对超重或肥胖和无症状高尿酸血症患者循环脂肪因子谱的影响。
这是一项单中心、随机、对照临床试验，共纳入 130 名无症状高尿酸血症和肥胖患者。130 名患者中 117 名完成了最终分析，其中非布司他组 60 例，对照组 57 例。我们比较了 3 个月和 6 个月时的循环脂肪因子水平，包括高分子量（HMW） adiponectin、chemerin、omentin、单核细胞趋化蛋白-1、asprosin、成纤维细胞生长因子 21、neuregulin-4、瘦素、抵抗素、vaspin、visfatin、adipsin，并评估了 XOR 活性（ΔXOR）变化与 febuxostat 治疗后脂肪因子水平（Δadipokines）变化之间的相关性。
结果显示，与对照组相比，HMW adiponectin 和 omentin 水平在 3 或 6 个月时升高，chemerin 和 asprosin 水平降低。此外，ΔXOR 活性与 Δasprosin 呈正相关。进一步在多元线性回归分析中调整甘油三酯（ΔTG）和血清尿酸（ΔSUA）后，我们发现 ΔXOR 活性与 Δasprosin 独立相关。
本研究可能为非布司他可减轻超重或肥胖和无症状高尿酸血症患者循环脂肪因子水平失衡提供重要证据。此外，我们观察到非布司他治疗后 asprosin 水平变化与 XOR 活性变化之间存在正相关。
